Výsledky vyhledávání - "Fredriksen AB"

Akademický článek

The Effect of Specific Strength Training on Throwing Velocity in Overarm Throwing: A Systematic Review.

Autor: Fredriksen AB; Department of Sports Sciences and Physical Education, Nord University, Levanger, Norway., van den Tillaar R; Department of Sports Sciences and Physical Education, Nord University, Levanger, Norway. roland.v.tillaar@nord.no.

Publikováno v: Sports medicine - open [Sports Med Open] 2024 Nov 09; Vol. 10 (1), pp. 122. Date of Electronic Publication: 2024 Nov 09.

Zobrazit plný text záznamu

Akademický článek

A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses.

Autor: Kuczkowska K; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway. kkuczkowska@nykode.com., Bjerkan L; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Stubsrud E; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Husbyn HC; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Chellappa S; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway.; Veterinærinstituttet, Elizabeth Stephansens Vei 1, 1433, Ås, Norway., Hauge A; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Skarshaug R; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Torgersen ML; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Heim JB; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Jørgensen MJ; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Wold CW; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Schleimann MH; Department of Clinical Medicine/Infectious Diseases, Aarhus University, Palle Juul-Jensens Boulevard 45, 8200, Aarhus N, Denmark., Tolstrup M; Department of Clinical Medicine/Infectious Diseases, Aarhus University, Palle Juul-Jensens Boulevard 45, 8200, Aarhus N, Denmark., Granum S; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Fredriksen AB; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Pedersen MW; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Norheim G; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway.

Publikováno v: Scientific reports [Sci Rep] 2023 Nov 02; Vol. 13 (1), pp. 18902. Date of Electronic Publication: 2023 Nov 02.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial.

Autor: Hillemanns P; Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany., Denecke A; Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany., Woelber L; Department of Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Böhmer G; IZD Institut für Zytologie und Dysplasie, Hannover, Germany., Jentschke M; Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany., Schjetne KW; Nykode Therapeutics ASA, Oslo, Norway., Bruins Slot KMH; Nykode Therapeutics ASA, Oslo, Norway., Fredriksen AB; Nykode Therapeutics ASA, Oslo, Norway.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Nov 14; Vol. 28 (22), pp. 4885-4892.

Zobrazit plný text záznamu

Akademický článek

The Magnitude and IgG Subclass of Antibodies Elicited by Targeted DNA Vaccines Are Influenced by Specificity for APC Surface Molecules.

Autor: Braathen R; K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway; and ranveig.braathen@medisin.uio.no bjarne.bogen@medisin.uio.no., Spång HCL; K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway; and., Lindeberg MM; K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway; and., Fossum E; K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway; and., Grødeland G; K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway; and., Fredriksen AB; K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway; and., Bogen B; K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway; and ranveig.braathen@medisin.uio.no bjarne.bogen@medisin.uio.no.; Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway.

Publikováno v: ImmunoHorizons [Immunohorizons] 2018 Jan 18; Vol. 2 (1), pp. 38-53. Date of Electronic Publication: 2018 Jan 18.

Zobrazit plný text záznamu

Akademický článek

Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination.

Autor: Grodeland G; K.G. Jebsen Center for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway; gunnveig.grodeland@medisin.uio.no bjarne.bogen@medisin.uio.no., Fredriksen AB; Vaccibody AS, 0349 Oslo, Norway., Løset GÅ; Center for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway.; Department of Biosciences, University of Oslo, 0316 Oslo, Norway., Vikse E; K.G. Jebsen Center for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway., Fugger L; Institute of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark; and.; Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology and Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, United Kingdom., Bogen B; K.G. Jebsen Center for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway; gunnveig.grodeland@medisin.uio.no bjarne.bogen@medisin.uio.no.; Center for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, 0027 Oslo, Norway.

Publikováno v: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2016 Nov 01; Vol. 197 (9), pp. 3575-3585. Date of Electronic Publication: 2016 Sep 26.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání